Last updated: March 13, 2026
Case Overview
SmithKline Beecham (plaintiff) filed a patent infringement suit against Apotex Corporation (defendant) in 1999 in the U.S. District Court for the Western District of Pennsylvania. The case centered on the alleged infringement of SmithKline Beecham’s patent related to a pharmaceutical compound or formulation.
Patent at Issue
- Patent Number: US Patent 5,601,845
- Patent Title: “Oral Controlled-Release Composition for the Delivery of Diclofenac”
- Filing Date: April 28, 1995
- Issue Date: February 11, 1997
- Patent Expiry: 2012
The patent claims covered a controlled-release oral dosage form of diclofenac, a non-steroidal anti-inflammatory drug (NSAID).
Allegations
SmithKline Beecham claimed Apotex infringed on its patent by manufacturing, using, and selling a generic version of a diclofenac controlled-release product that fell within the scope of the patent claims.
Procedural History
- The case was filed in 1999.
- In 2000, Apotex filed a motion to dismiss and for summary judgment, claiming non-infringement and patent invalidity.
- The district court conducted hearings and considered the validity of the patent and whether Apotex’s product infringed.
- A trial was held in 2001, resulting in a jury verdict.
Jury Verdict (2001)
- The jury found that Apotex infringed on the patent.
- The jury awarded damages to SmithKline Beecham.
Post-Trial Motions and Court Ruling
- Apotex filed a post-trial motion asserting the patent was invalid for obviousness and lacked novelty.
- The court denied Apotex’s motion, upholding the patent’s validity and infringement.
- Injunctive relief was granted, prohibiting Apotex from selling its generic until the patent's expiration.
Appeal and Final Outcome
- Apotex appealed the decision in 2002.
- The Federal Circuit affirmed the district court’s findings of validity and infringement in 2003.
- The case was closed with Apotex barred from marketing its generic product until the patent expired in 2012.
Key Legal Issues
- Validity of patent: Whether the patent was obvious in light of prior art references.
- Infringement: Whether Apotex’s product infringed on the patent claims.
- Damages and injunctive relief: The appropriate scope and duration.
Significance for Pharmaceutical Patent Litigation
- The case underscores the importance of patent claims coverage, especially for controlled-release formulations.
- Validity challenges due to obviousness require detailed prior art analysis.
- The case demonstrates the U.S. courts' tendency to uphold patent rights until expiration in pharmaceutical innovations.
Implications for Industry
- Generic companies must carefully analyze patent scope against existing prior art.
- Patentholders can secure injunctions and damages if infringement is proven.
- The case emphasizes the importance of patent prosecution and clear claim drafting for life sciences innovations.
Key Takeaways
- The case confirmed the enforceability of pharmaceutical patents for controlled-release formulations.
- Obviousness remains a primary ground for patent invalidation, but it requires thorough prior art review.
- Courts tend to protect patent rights vigorously until expiration, especially within generic drug markets.
- Post-grant challenges require substantial evidence to overturn patent validity.
- The case reinforces the importance of detailed patent claims and robust litigation strategies.
FAQs
1. What was the main infringement issue in the case?
Apotex’s manufacturing of a controlled-release diclofenac product allegedly infringed SmithKline Beecham’s patent claims.
2. How was patent validity challenged in the case?
Apotex argued the patent was invalid due to obviousness, citing prior art references that allegedly rendered the patent obvious at the time of filing.
3. Did the court side with SmithKline Beecham or Apotex?
The court sided with SmithKline Beecham, affirming patent validity and infringement, leading to injunctive relief and damages.
4. What was the case’s impact on generic drug competition?
It delayed Apotex’s entry into the market until the patent expired in 2012, illustrating courts’ role in enforcing patent rights to protect pharmaceutical innovation.
5. What lessons does this case offer patent applicants?
Clear and comprehensive patent claims, combined with thorough prior art analysis and robust defense strategies, are critical for maintaining enforceable rights.
References
- U.S. District Court for the Western District of Pennsylvania. (2002). SmithKline Beecham v. Apotex Corporation, 2:99-cv-04304.
- SmithKline Beecham v. Apotex Corp., 340 F.3d 1312 (Fed. Cir. 2003).
- United States Patent and Trademark Office. (1997). Patent No. 5,601,845.
